Back to today’s briefing

Story perspectives

Myriad Genetics Shares Plummet Amidst Industry Challenges

1/16/2025

48 11

Summary

Story summary

Myriad Genetics, Inc. (NASDAQ: MYGN) is grappling with a tumultuous year, as its shares plummeted to a 52-week low of $12.85, reflecting a staggering 37.29% decline. Analysts have downgraded the stock due to mounting industry pressures and lowered growth forecasts. Despite an 11% revenue growth, challenges like Medicaid cuts and fierce competition loom large as the company targets a 12% revenue CAGR by 2026.

1 of 1

Story summary

Myriad Genetics, Inc. (NASDAQ: MYGN) is grappling with a tumultuous year, as its shares plummeted to a 52-week low of $12.85, reflecting a staggering 37.29% decline. Analysts have downgraded the stock due to mounting industry pressures and lowered growth forecasts. Despite an 11% revenue growth, challenges like Medicaid cuts and fierce competition loom large as the company targets a 12% revenue CAGR by 2026.